GlassScriptPhysician profile
Robert L Sawyer
NPI 1487616892
$4,990.34
in general payments reported to CMS, 2019-2025
26 companies · $38.99 in 2025
The $38.99 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $106 · 2021: $959 · 2022: $1,441 · 2023: $1,764 · 2024: $21.73 · 2025: $38.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Education: $97.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.09 |
| Education | $97.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.58 | 2019-2023 | Rinvoq, Skyrizi, Linzess |
| Braintree Laboratories, INC. | $535.55 | 2019-2022 | |
| Pfizer INC. | $500.76 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $455.00 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $385.55 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.70 | 2019-2023 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $211.30 | 2021-2023 | |
| Celgene Corporation | $192.82 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $166.86 | 2019 | |
| Organon LLC | $133.41 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $132.62 | 2022-2023 | Dupixent |
| Redhill Biopharma INC. | $91.24 | 2021-2023 | Talicia |
| Ferring Pharmaceuticals INC. | $88.57 | 2021-2023 | Cimzia, Rebyota |
| Amgen INC. | $85.53 | 2021-2023 | Amjevita, Avsola |
| Ardelyx, INC. | $70.60 | 2022-2023 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $56.98 | 2021-2023 | |
| Lucid Diagnostics INC. | $42.89 | 2021 | |
| Qol Medical, LLC | $36.03 | 2019-2023 | Sucraid |
| Daiichi Sankyo INC. | $26.32 | 2023 | Injectafer |
| Boston Scientific Corporation | $25.66 | 2023 | Watchman Flx |
| Celltrion USA INC. | $21.17 | 2023 | Yuflyma |
| Oxford Immunotec USA INC | $17.94 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.98 | 2019 | |
| Ucb, INC. | $12.82 | 2019 | |
| Olympus America INC. | $12.46 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sawyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.